The accuracy of the anti-mitochondrial antibody and the M2 subtype test for diagnosis of primary biliary cirrhosis: a meta-analysis

Hu, Shiling; Zhao, Feng-Rong; Wang, Qingsong; Chen, Weixian

doi:10.1515/cclm-2013-0926

Cited by 50 publications

(29 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, serum antibodies specific for PBC are the other pivotal biomarkers for making a PBC diagnosis. It is well known that AMAs, especially AMA-M2, are excellent markers with high specificity and sensitivity for the routine diagnosis of PBC [24]. AMAs are present in 95% of PBC patients; however, 5% of patients with PBC are AMA-negative [25].…”

Section: Discussionmentioning

confidence: 99%

Microarray Expression Profile of Circular RNAs in Plasma from Primary Biliary Cholangitis Patients

Zheng¹,

Li²,

Wang³

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Circular RNAs (circRNAs) play a crucial role in the occurrence of several diseases, including autoimmune diseases. However, their role in primary biliary cholangitis (PBC) remains unclear. Here, we aimed to determine the circRNA expression profile in plasma from PBC patients and further explore the value of circRNA in diagnosing PBC. Methods: CircRNA microarrays were used to determine circRNA expression profiles in plasma samples from 6 PBC patients and 6 healthy controls. Statistical analyses identified differentially expressed circRNAs, and these circRNAs were verified by qRT-PCR in 29 PBC patients and 30 healthy controls. MicroRNA (miRNA) target prediction software identified putative miRNA response elements (MREs), which were used to construct a map of circRNA-miRNA interactions for the differentially expressed circRNAs. Results: Our results indicated that there were 18 up-regulated and 4 down-regulated circular RNAs in the plasma from PBC patients compared with that from healthy individuals. Among the differentially expressed circRNAs, hsa_circ_402458 (P=0.0033), hsa_circ_087631 and hsa_circ_406329 (P=0.0185) were up-regulated, and hsa_circ_407176 (P=0.0066) and hsa_circ_082319 were down-regulated in the PBC group versus the healthy group as demonstrated by qRT-PCR. In particular, hsa_circ_402458 was significantly higher in PBC patients not receiving UDCA treatment than in PBC patients receiving UDCA treatment (P=0.0338). The area under the receiver operating characteristic curve for hsa_circ_402458 for diagnosing PBC was 0.710 (P=0.005). For hsa_circ_402458, two putative miRNA targets, hsa-miR-522-3p and hsa-miR-943, were predicted. Conclusions: circRNA dysregulation may play a role in PBC pathogenesis, and hsa_circ_402458 shows promise as a candidate biomarker for PBC.

show abstract

Section: Discussionmentioning

confidence: 99%

Microarray Expression Profile of Circular RNAs in Plasma from Primary Biliary Cholangitis Patients

Zheng¹,

Li²,

Wang³

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…AMAs: AMAs, including AMAs-M2, are a specific and sensitive marker for the diagnosis of PBC[9,10,93,94]. The existing evidence shows that AMAs and AMAs-M2 have excellent diagnostic value, with high specificity and sensitivity for PBC[93].…”

Section: Serological Featuresmentioning

confidence: 99%

“…The existing evidence shows that AMAs and AMAs-M2 have excellent diagnostic value, with high specificity and sensitivity for PBC[93]. Compared with AMAs-M2, AMAs is a faster and more comprehensive diagnostic marker[93].…”

Section: Serological Featuresmentioning

confidence: 99%

See 1 more Smart Citation

Recent advances in the diagnosis and treatment of primary biliary cholangitis

Huang¹

2016

WJH

View full text Add to dashboard Cite

Primary biliary cholangitis (PBC), formerly referred to as primary biliary cirrhosis, is an infrequent progressive intrahepatic cholestatic autoimmune illness that can evolve into hepatic fibrosis, hepatic cirrhosis, hepatic failure, and, in some cases, hepatocellular carcinoma. The disease itself is characterized by T-lymphocyte-mediated chronic non-suppurative destructive cholangitis and elevated serum levels of extremely specific anti-mitochondrial autoantibodies (AMAs). In this article, we will not only review epidemiology, risk factors, natural history, predictive scores, radiologic approaches (e.g., acoustic radiation force impulse imaging, vibration controlled transient elastography, and magnetic resonance elastography), clinical features, serological characteristics covering biochemical markers, immunoglobulins, infections markers, biomarkers, predictive fibrosis marker, specific antibodies (including AMAs such as AMA-M2), anti-nuclear autoantibodies [such as anti-multiple nuclear dot autoantibodies (anti-sp100, PML, NDP52, anti-sp140), anti-rim-like/membranous anti-nuclear autoantibodies (anti-gp210, anti-p62), anti-centromere autoantibodies, and some of the novel autoantibodies], histopathological characteristics of PBC, diagnostic advances, and anti-diastole of PBC. Furthermore, this review emphasizes the recent advances in research of PBC in terms of therapies, including ursodeoxycholic acid, budesonide, methotrexate, obeticholic acid, cyclosporine A, fibrates such as bezafibrate and fenofibrate, rituximab, mesenchymal stem cells transplant, and hepatic transplant. Currently, hepatic transplant remains the only optimal choice with acknowledged treatment efficiency for end-stage PBC patients.

show abstract

“…The diagnosis of PBC is typically based on abnormal serum biochemical parameters, such as the presence of anti-mitochondrial antibody (AMA), increased alkaline phosphatase (ALP), and a positive reaction for gamma-glutamyl transferase (GGT) 9 . Serum AMA, especially the AMA-M2 subtype, is regarded as one of the most specific and acceptable diagnostic indicators for PBC 10, 11 . Since the presence of AMA was first recognized by Walker et al .…”

Section: Introductionmentioning

confidence: 99%

Detection of AMA-M2 in human saliva: Potentials in diagnosis and monitoring of primary biliary cholangitis

Hou

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Serum anti-mitochondrial antibody type 2 (AMA-M2) is considered as a pivotal biomarker for the diagnosis of primary biliary cholangitis (PBC). However, serological tests have many limitations, including inconvenience, invasiveness, and infection risks. Thus, a less invasive approach to detect AMA-M2 titer is desirable. We examined salivary AMA-M2 of potential PBC patients and found that AMA-M2 could be detected only in saliva of serum AMA-M2-positive PBC patients, but not in saliva of serum AMA-M2-negative PBC patients, oral lichen planus patients (OLP) patients, or healthy controls. Furthermore, the concentration of salivary AMA-M2 was positively correlated with the amount of serum AMA-M2 in patients. The salivary inflammatory cytokines were increased in the PBC, consistent with the results of serum test. These findings indicated that saliva might be a less invasive and cost-effective medium to accurately test for AMA-M2 levels and this is a promising development for the diagnosis and monitoring of PBC.

show abstract

The accuracy of the anti-mitochondrial antibody and the M2 subtype test for diagnosis of primary biliary cirrhosis: a meta-analysis

Cited by 50 publications

References 64 publications

Microarray Expression Profile of Circular RNAs in Plasma from Primary Biliary Cholangitis Patients

Microarray Expression Profile of Circular RNAs in Plasma from Primary Biliary Cholangitis Patients

Recent advances in the diagnosis and treatment of primary biliary cholangitis

Detection of AMA-M2 in human saliva: Potentials in diagnosis and monitoring of primary biliary cholangitis

Contact Info

Product

Resources

About